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A B S T R A C T
Toxoplasma gondii is an obligate intracellular parasite with global incidence. The acute infection, toxoplasmosis,
is treatable but current regimens have poor host tolerance and no cure has been found for latent infections. This
work builds upon a previous high throughput screen which identified benzoquinone acyl hydrazone (KG8) as the
most promising compound; KG8 displayed potent in vitro activity against T. gondii but only marginal in vivo
efficacy in a T. gondii animal model. To define the potential of this new lead compound, we now describe a
baseline structure-activity relationship for this chemotype. Several derivatives displayed IC50's comparable to
that of the control treatment pyrimethamine with little to no cytotoxicity. The best of these, KGW44 and KGW59,
had higher metabolic stability than KG8. In an in vivo T. gondii murine model, KGW59 significantly increased
survivorship. This work provides new insights for optimization of this novel chemotype.
1. Introduction
Toxoplasma gondii is a protozoan parasite capable of infecting vir-
tually all classes of warm-blooded vertebrates. Initial infection often
occurs from contaminated food and water or exposure to oocysts shed
by members of the Felidae family. Upon host infection, the disease
toxoplasmosis can occur. Acute toxoplasmosis is frequently described as
mild flu-like symptoms, but healthy individuals will often be asymp-
tomatic, while transition to a life-long latent infection is common
(Tenter et al., 2000).
The immunocompromised populations who carry the parasitic in-
fection require lifelong prophylactic treatment to prevent parasite in-
duced encephalitis. Primary infections that occur in mothers during
pregnancy can cause congenital toxoplasmosis in the fetus due to the
ability of the parasite to cross the placenta. Such fetal infections can
result in disastrous birth defects such as hydrocephaly and other mal-
formations, causing T. gondii to be leading cause of birth defects
worldwide (Tenter et al., 2000).
Current treatments exist to control acute toxoplasmosis, but the is-
sues remain with poor host tolerance and frequent severe complications
(Fung and Kirschenbaum, 1996). Front-line treatment most commonly
includes pyrimethamine in combination with sulfadiazine but is asso-
ciated with bone marrow toxicity and allergic reactions (Fung and
Kirschenbaum, 1996). Some symptoms have been mitigated with the
co-administration of folinic acid. Because of this, there is an imperative
need for new therapeutics to be developed to combat acute infection.
No FDA approved treatment has yet to be established for congenital
toxoplasmosis, but it has been treated with clindamycin with varying
degrees of success (McFarland et al., 2016).
While acute stage toxoplasmosis has been mitigated with current
treatments, the latent infection has remained resistant to clearance and
is presently life-long (Neville et al., 2015). Research efforts have pro-
duced few promising lead candidates against the chronic stage (Neville
et al., 2015; McFarland et al., 2016).
A high-throughput phenotypic screen (HTS) of a chemical library
produced a small collection of drug-like compounds with demonstrated
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efficacy against both Plasmodium falciparum and T. gondii in vitro
(Guiguemde et al., 2010). The three compounds with the highest po-
tency against T. gondii were further characterized as potential leads for
further optimization and development (Sanford et al., 2018). The most
promising of these was KG8 (Fig. 1). Given that kinases are thought to
be promising T. gondii drug targets (Kamau et al., 2012), it is interesting
to note that the closely related compound poloxin (Fig. 1), a derivative
of thymoquinone, is an inhibitor of host polo-like kinase 1 (Liao et al.,
2010). KG8 and closely related analogues have been previously shown
to inhibit cyclooxgenase-2 and 5-lipoxygenase (Misra et al., 2013) in
the host, and potentiate nerve growth factor (Eguchi et al., 2000). KG8
is also an acyl hydrazone derivative of the antibiotic isoniazid; how-
ever, the latter was inactive against T. gondii in vitro (Sanford et al.,
2018). These data may suggest a host target of KG8, or potentially a
parasite homolog target.
We now describe our initial work to assess the potential of this
chemotype by the generation of a small library of chemical analogues to
increase potency and selectivity against T. gondii. We identified two
promising derivatives (KGW44 and KGW59) and assessed their physi-
cochemical and ADME profiles and their in vivo efficacy in a T. gondii
animal model.
Fig. 1. KG8 and poloxin structures.
Table 1
IC50 values of KG8 and derivatives against T. gondii strains and HFF.
Derivative ID RH T. gondii IC50 (μM) PRU T. gondii IC50 (μM) HFF IC50 (μM)
KG81 2.3 2.5 28.0
KGW15 2.0 – >100
KGW42 2.0 – >100
KGW43 3.8 – >100
KGW64b 0.91 78 >100
KGW44a 0.20 0.99 > 100
KGW54 1.2 2.2 > 100
KGW65b 0.66 > 100 >100
KGW45 40 – >100
KGW66b >100 – >100
KGW68b 3.8 – >100
KGW59a 0.13 1.4 > 100
KGW72 13 – >100
KGW73 >100 – >100
Derivatives of KG8 (Sanford et al., 20181) were screened against both RH-dTom
and Pru-dTom T. gondii.
a Compounds that were effective in inhibiting T. gondii viability were se-
lected for further cell viability screening. All compounds were also screened in a
cell viability screen against human foreskin fibroblasts (HFF). No compound
was highly toxic against HFF.
b Compounds KGW64-68 were found to be auto fluorescent and were ex-
cluded from further analysis.
Fig. 2. KGW structures.
Table 2
Expanded mammalian cell viability screen results and point mutagenicity.
Derivative ID NR-9456
IC50 (μM)
U2OS IC50
(μM)
HEK293
IC50 (μM)
HCO4
IC50 (μM)
Ames Assay
KG81 > 100 >100 0.97 28 Negative
KGW44 >100 >100 >100 >100 Negative
KGW59 >100 >100 >100 >100 Negative
Derivatives of KG8 (Sanford et al., 20181) that were identified as effective in the
preliminary screen (Table 1) were further screened for possible cell viability
inhibition in NR-9456, U2OS, and HEK293.
Potential point mutagenicity was also screened for with the use of a bacterial
reversion assay (Ames Assay).
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2. Methods
2.1. Experimental compounds
The synthesis of the KG8 derivatives is described in the supple-
mental material section.
2.2. Cell line maintenance
Human foreskin fibroblasts (HFF), human osteosarcoma cells (U-
20S), human embryonic kidney cells (HEK-293), human liver cells (HC-
04), and murine macrophages (NR-9456) were all obtained from ATCC.
HFF, U-20S, and all T. gondii strains (RH-dTom, ME49 and PRU) used
were maintained in DMEM media (Lonza) supplemented with 10% heat
inactivated Hyclone bovine serum (GE Healthcare Life Sciences),
HyClone 2mM L-glutamine (GE Healthcare Life Sciences), 100 μg/mL
penicillin and streptomycin (Corning), 10% Medium 199 (Corning) and
gentamicin sulfate (Corning) at 36.5 °C with 5% CO2. HEK-293 and HC-
04 were maintained in the same medium without the addition of
Medium 199. Macrophage NR-9456 was grown with the addition of
1mM sodium pyruvate as recommended.
2.3. Parasite strains
RH (Type I) and PRU (Type II) strain T. gondii with inserted fluor-
escent transgene dimerized Tomato (dTom) were used for in vitro
growth inhibition experiments. ME49 (Type II) strain T. gondii was used
for the in vivo survivorship challenge in a murine model.
2.4. T. gondii growth inhibition in vitro screens (IC50)
HFF cells were plated in 96 well plates at approximately
20,000 cells per well and allowed to grow until confluent. Once con-
fluency was reached, 2000 RH-dTom (or 8000 PRU-dTom) tachyzoites
were added to each well and the plates were incubated at 37 °C for 24 h
(48 h for PRU) to allow for infection. Media was then replaced, and
compounds dissolved in DMSO (Fischer Scientific) were added at in-
creasing concentration from 0 to 100 μM. The concentration of DMSO
did not exceed 1% in all assays to prevent cytotoxicity. All concentra-
tions were performed in duplicate and pyrimethamine was used as a
positive control. A fluorescent reading was then taken with a BioTek
Snergy HT plate reader at 530/25 excitation and 590/25 emission for 5
days. IC50s were determined after day 5 where half of the relative
fluorescent units (RFU) were seen.
2.5. Mammalian cell line cytotoxicity screens (IC50)
Mammalian cell viability was determined using human foreskin
Fig. 3. Host cell pre-treatment and ex-
tracellular tachyzoite exposure results.
(a.) HFF cells were pretreated with com-
pounds at 10 μM and allowed to incubate at
37 °C for 24 h. Cells were then washed and
infected with 2000 RH-dTom tachyzoites.
(b.) Isolated RH-dTom tachyzoites were
pretreated with compounds at 10 μM for
4 h at room temperature, then 2000 para-
sites were used to infect HFF. Fluorescent
readings were taken 5 days post-infection
for both experiments. (p value = **0.00007;
*0.002).
Table 3
Physiochemical parameters, solubility, and plasma protein binding of top KGW
compounds.
Identifier cPPBa (% Bound) PSAb (A2) gLogD (pH 7.4) Sol6.5 c(ug/mL)
KG81 > 99.5 71.4 3.9 3.1–6.3
KGW44 84.3 101.7 4.9 < 1.6
KGW59 ND 127.7 > 5.3 < 1.6
(ND: No chromatographic peak under cPPB conditions) (Sanford et al., 20181).
a Plasma protein binding was estimated using a chromatographic method.
b PSA values were calculated through the ChemAxon chemistry cartridge
with JChem from Excel.
c Kinetic solubility was determined by nephelometry after 30min at room
temperature.
Table 4
Metabolic stability of KGW44 and KGW59.
Compound ID Microsome
species
T1/2 (min) CLint, in vitro (μL/
min/mg protein)
Predicted EH
KG81 Human 9 129 0.88
Mouse < 2 >886 N/A
KGW44 Human 83 21 0.45
Mouse 9 99 N/A
KGW59 Human 111 16 0.38
Mouse 37 46 0.50
Metabolic stability was assessed in both human and mouse liver microsomes.
The half-life (T1/2), intrinsic clearance in vitro (CLint), and the predicted hepatic
extraction ratios (EH) were determined (Sanford et al., 20181).
Fig. 4. In vivo survival following compound treatment in a murine model.
Swiss-Webster mice were infected with 5000 ME49 T. gondii tachyzoites and
then subsequently treated with respective compound for 10 days at 5 mg/kg.
Survival was quantified over 40 d using a Kaplan-Meier curve. (p
value = 0.004*).
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fibroblasts (HFF), osteosarcoma (U-20S), embryonic kidney (HEK-283),
hepatic carcinoma (HC-04), and a murine derived macrophage (NR-
9456) cell line that were plated with approximately 20,000 cells per
well and let grown until confluent. Once confluent, cells were treated
with increasing compound concentrations from 0 to 100 μM for 24 h.
This was followed by an Alamar Blue assay with 0.5mM resazurin at
37 °C with 5% CO2 for 4 h. All concentrations were performed in du-
plicate. A fluorescent reading was then taken with a BioTek Snergy HT
plate reader at 530/25 excitation and 590/25 emission. Host cell via-
bility was determined by comparing the treatments with no compound
treatment as 100% viability.
2.6. Bacterial reverse mutation assay
A modified form of the Ames assay (Environmental Bio-Detection
Products Inc.) with Salmonella typhimurium (TA100 strain) was used to
detect DNA single point mutagenicity. Compounds were tested at con-
centrations of 3x the averaged T. gondii IC50 values (Table 1) in sets of
48 replicates. A count of revertant colonies was performed and com-
pared to the natural revertant control with the unpaired Student's t-test
to assess statistical significance.
2.7. Host cell and extracellular parasite pre-treatment assay
HFF cells were grown in 96 well plates to confluency. 10 μM of
respective compound was added to the wells (performed in triplicate).
After 24 h of compound exposure, cells were then washed twice with
D10 media. Cells were then infected with 20,000 RH tachyzoites/mL
and parasite growth was quantified by fluorescence for 5 days post-
infection.
To evaluate the effect of compound exposure to free tachyzoites,
10 μM of respective compound was added to RH-dTom tachyzoites
isolated from culture and resuspended in D10 media at 10e6 tach-
zyoites/mL. Exposure to compound lasted 4 h at 37 °C. After treatment,
tachyzoites were centrifuged and washed twice. Confluent HFF in 96
well plates were then infected with 2000 treated tachyzoites per well.
Tachyzoite growth was quantified by fluorescence at 5 days post in-
fection.
2.8. Calculated physicochemical properties
Polar surface area (PSA) and lipophilicity (cLogD) values were as-
sesed by the ChemAxon chemistry cartridge via JChem for Excel
Software. Aqueous solubility of the most potent three compounds was
determined by dissolving in DMSO and then spiked into either pH 6.5
PBS or 0.01M HCl (pH 2.0). Samples were then analyzed 30min after
nephelometry to determine a solubility range. Partition coefficient va-
lues were then analyzed at pH 7.4 through chromatographic retention
properties against standard compounds with known values through
gradient HPLC. Chromatography-based protein binding values (cPPB)
were then determined by correlation of known chromatographic re-
tention properties by using a human albumin column against a standard
series of compounds with known cPPB values (Valko et al., 2003). To
determine metabolic stability, compounds were incubated with liver
microsomes at 1 μM from both humans and mice at 37 °C at a protein
concentration of 0.4 mg/mL. Reactions were initiated by the addition of
an NADPH-regenerating system. Reactions were then quenched at
varying time points (2, 30, and 60min) and compound concentrations
were then determined through LCMS.
2.9. Efficacy in vivo
Female Swiss Webster mice were obtained from Charles' River. At 2
months old, mice were infected intraperitoneally with 5000 ME49 ta-
chyzoites. Simultaneously, treatment began with experimental com-
pounds at 5mg/kg (n=10), pyrimethamine at 5mg/kg (n=20) or
solvent (n=24) given once per day. Doses was determined for all three
compounds by prior screening for toxicity. All experimental compounds
and pyrimethamine were dissolved in 5% DMSO, 47.5% Propylene
glycol (Sigma-Aldrich), and 47.5% Kollisolv (Sigma-Aldrich). Mice
were weighed daily to assess overall health and to monitor weight
changes indicative of infection. P values were obtained through the use
of IBM STSS Statistics 22 software. All in vivo studies were in-
stitutionally approved and carried out under IACUC #12-062-10.
3. Results and discussion
3.1. Primary screen for RH strain T. gondii and human fibroblast (HFF)
cytotoxicity
Thirteen derivatives of KG8 (Fig. 2) were initially screened against
the RH strain T. gondii for their potency in growth inhibition, and in
human foreskin fibroblasts for host cell cytotoxicity (Table 1). We first
discovered that replacing the 4-pyridyl substructure with a phenyl
(KGW15) did not lower potency against T. gondii. Further, compounds
in which the para position of the phenyl substructure was substituted
with electron-donating (KGW42, 43, 64) and electron-withdrawing
(KGW44, 54) groups were also quite active with IC50s in the range of
0.20–3.8 μM; of these KGW64 and KGW44 were the most potent.
Compound KGW65, the 3-pyridyl isostere of KG8, was marginally more
potent than the parent compound. However, replacing the 4-pyridyl
substructure with an imidazole (KGW45) or cyclohexyl (KGW66) sig-
nificantly weakened or abolished activity, respectively. Removal of the
acyl hydrazone carbonyl (KGW68) and adding a nitro group (KGW59)
increased potency by an order of magnitude. Replacing the acyl hy-
drazone of KG8 with an acyl oxime ether to afford the poloxin analog
KGW72 reduced potency 6-fold. KGW73, a saturated analog of the
benzoquinone substructure, was inactive. Finally, none of the com-
pounds decreased HFF viability at up to 100 μM concentration.
3.2. Screen for activity against T. gondii PRU strain
The five compounds (KGW64, 44, 54, 65, and 59) with IC50 values
less than 2 μM against T. gondii strain RH were tested against strain PRU
(Type II lineage) which is considered less virulent and more re-
presentative of natural infections (Howe and Sibley, 1995). All five
compounds were less active against the PRU strain; notably, KGW65
was completely inactive and KGW64 was only weakly active. KGW44
(IC50= 0.99 μM) was the most potent derivative, followed by KGW59
(IC50= 1.4 μM). From these data, KGW44 and KGW59 were selected
for further profiling.
3.3. Expanded mammalian cell cytotoxicity screen
KGW44 and KGW59 were tested against the U-2OS (osteosarcoma),
HEK-293 (kidney), HC-04 (liver) and NR-9456 (macrophage) cell lines
to further assess their selectivity against T. gondii (Table 2). Neither
compound showed any effects on these cells at concentrations up to
100 μM.
3.4. Bacterial reverse mutation assay
Compounds KGW44 and KGW59 were tested at 0.75 μM (ca. 3x
average T. gondii IC50) for their capacity to induce DNA point mutations
in a bacterial model (Ames assay) with Salmonella typhimurium strain
TA100; neither compound was mutagenic.
3.5. Pre-treatment assays
To probe a possible mode of action, both HFF cells and tachyzoites
were pre-treated with 10 μM of KGW44 and KGW59. KGW59 pre-
treatment of HFF cells prior to infection with tachyzoites resulted in a
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decrease of parasite growth to 30.2% of control (p=0.00007; Fig. 3).
When tachyzoites were exposed to KGW59 prior to infection no sig-
nificant change in growth was found. When HFF cells were treated with
KGW44 no significant change in growth was measured. However, when
tachyzoites were treated with KGW44 prior to infection, percent growth
was reduced to 60.3% of control (p=0.002; Fig. 3). From these data, it
can be reasoned that KGW59 may be taken up by the host cell to effect
T. gondii growth while KGW44 may elicit a direct effect on the extra-
cellular parasite prior to invasion.
3.6. Physicochemical and in vitro ADME
Data in Table 3 indicate that KGW44 and KGW59 were more lipo-
philic and less soluble than KG8. The three compounds had calculated
polar surface area (PSA) values ranging from 72 to 128 A2 indicating
that polarity would not be a rate-limiting factor for membrane per-
meability (Palm et al., 1997). Plasma protein binding for KGW44
(84.3%) was considerably lower than that of KG8 which had a cPPB
value of> 99.5%. Metabolic stability testing in both human and mouse
liver microsomes (Table 4) indicated that both KGW44 and KGW59
were considerably more stable than KG8. The intrinsic clearance (CLint)
and predicted hepatic extraction ratio (EH) values indicate that all of
the compounds were more rapidly metabolized in mouse vs. human
liver microsomes. The metabolic instability of these compounds may be
a consequence of their twin tert-butyl groups (Barnes-Seeman et al.,
2013; Westphal et al., 2015) and electrophilic benzoquinone sub-
structure.
3.7. Efficacy in vivo
KGW44 and KGW59 were tested for their capacity to increase sur-
vivorship in Swiss-Webster mice following a lethal challenge with 5000
ME49 strain T. gondii tachyzoites (Fig. 4). Compounds were adminis-
tered IP at 5.0 mg/kg/day for 10 days post-infection. Pyrimethamine
was included as a positive control and treated mice displayed 90%
survivorship, while 45% of KGW59-treated mice survived, and 0% of
KGW44-treated mice survived.
4. Conclusion
To define the potential of benzoquinone acyl hydrazone KG8 as a
new lead against T. gondii, we performed a baseline structure-activity
relationship for this new chemotype. Several derivatives displayed
IC50's comparable to that of pyrimethamine with little to no cytotoxi-
city. The best of these, KGW44 and KGW59, had higher metabolic
stability than KG8. In an in vivo T. gondii murine model, KGW59 sig-
nificantly increased survivorship. This work provides new insights for
optimization of this novel chemotype.
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